The quiet resolution of a cross-border arbitration dispute has removed a lingering overhang from Sellas Life Sciences, even as the biotech’s share price continues to trade in the shadow of a far more consequential catalyst: the approaching final analysis of its pivotal Phase 3 REGAL trial.
A Hong Kong-based arbitration tribunal at the HKIAC dismissed all claims the company had brought against Chinese partner 3D Medicines in late July, and on August 18 the award was enforced — with Sellas wiring roughly $1.0 million to cover legal costs. While the payment might look like a setback on the surface, the settlement clarifies a legal question without disturbing the underlying economics of the partnership. The licensing arrangement covering Greater China remains intact, meaning 3D Medicines still holds exclusive development and marketing rights to the vaccine candidate GPS in the region, and Sellas could still receive milestone payments of up to $191.5 million if the collaboration advances.
The cash outlay is immaterial against the company’s balance sheet. Sellas reported liquid assets of $138.3 million as of June 30, and its second-quarter net loss of $9.6 million — driven by $6.3 million in research spending and $4.4 million in administrative costs — leaves ample runway for the clinical programs that actually matter.
The 80th Event and the Silence Around It
The real story remains the REGAL study, a binary readout that has already reshaped the company’s shareholder base. The trial is approaching the pre-specified 80th event that triggers the final efficacy analysis, a process that includes database lock, blinded data review, and subsequent unblinding. No firm date has been given for that milestone, and the company has observed a self-imposed quiet period since CEO Angelos Stergiou hinted on LinkedIn that the threshold may have been reached.
The last officially confirmed count stood at 78 of 80 events, disclosed via the Chinese licensing partner. That gap between suggestion and confirmation has turned the stock into a study in speculative tension — one that has attracted institutional money even as it keeps retail traders guessing.
Media reports indicate institutional ownership has roughly doubled to just over 36 percent in recent weeks, with passive and index-linked funds now dominating the register. Multi-strategy and quant funds, by contrast, appear to have exited, which could dampen short-term trading volatility around the catalyst.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
A Stock That Has Already Run Far
The shares traded at €12.20 on Wednesday, up 1.7 percent after closing the prior session at €12.00. That modest gain follows a 2.4 percent dip the day before — a mild consolidation rather than a sell-off, and one that leaves the stock 14 percent above its 50-day average of €10.66. The year-to-date advance stands at an eye-catching 323 percent, though the equity remains 20 percent below its 52-week high of €15.25 reached in late June.
That extraordinary run has prompted scrutiny of the company’s compensation practices. Shareholders previously approved an expansion of the 2023 equity incentive plan by 20 million shares, including an award of 1.065 million restricted stock units to the CEO — a generous structure that raises legitimate questions about how much future gains might be diluted.
Management has so far resisted tapping the market for fresh capital. None of the $150 million at-the-market program with TD Cowen has been used, a signal that the company is content to sit on its cash cushion rather than refinance at current levels, preferring to wait for a potentially more favorable window.
Beyond the Trial: Politics and Pipeline
Stergiou has also been active in Brussels, participating in discussions with the European Parliament on the EU Biotech Act concerning approval pathways and market access. For a company whose fortunes hinge on a single registration study, such political engagement is increasingly part of the survival playbook rather than a luxury.
Meanwhile, the pipeline extends beyond REGAL. The Phase 2 study of SLS009 in newly diagnosed acute myeloid leukemia has enrolled 28 of a planned 80 patients, with topline data expected in the fourth quarter. Preclinical data on SLS009 in pancreatic cancer are also being prepared for clinical development at a leading academic institution.
The market capitalization of roughly €2.48 billion already embeds considerable confidence — a valuation that only hard clinical data can ultimately justify. The third-quarter results, scheduled for November 11, should provide the next official word on where the trial actually stands. Until then, every tick in the share price remains a bet on a signal that has yet to be formally delivered.
Ad
Sellas Life Sciences Stock: Buy or Sell?! New Sellas Life Sciences Analysis from August 26 delivers the answer:
The latest Sellas Life Sciences figures speak for themselves: Urgent action needed for Sellas Life Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 26.
Sellas Life Sciences: Buy or sell? Read more here...
